Emergent BioSolutions Inc
Emergent BioSolutions Inc (EBS) is a specialty biopharmaceutical company focused on public‑health countermeasures, including vaccines, therapeutics and related devices. The business mixes commercial products with government and public‑health contracts, and also offers contract manufacturing capacity — a model that can generate steady, often large-scale orders but can make revenue lumpy. With a market capitalisation of about $504.17M, EBS sits in the small‑cap space where operational setbacks or contract timing can have an outsized impact on the share price. Key investor considerations include the company’s exposure to government procurement cycles, regulatory scrutiny of manufacturing quality, and any product concentration or litigation. While a capable manufacturing footprint and specialist product portfolio can be attractive, execution risk and policy dependence are material. This summary is for educational purposes only and is not personal financial advice; suitability depends on your circumstances and you should seek independent advice if unsure.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Emergent BioSolutions' stock, believing it can rise to $13.5.
Financial Health
Emergent BioSolutions is performing well with solid revenue and cash flow, indicating good profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EBS
Navigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Government Contracts
A significant portion of revenue comes from government and public‑health contracts, which can provide scale but be lumpy and sensitive to policy decisions.
Products for Public Health
The company focuses on vaccines, therapeutics and devices for emergencies and infectious diseases — an area with enduring demand, though regulatory hurdles matter.
Manufacturing Risk & Reward
In‑house manufacturing can be a competitive advantage but brings operational and quality risks; past execution issues show how production affects value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
